Séverine Guiu

5PUBLICATIONS
56CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsPredictive and prognostic markersTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Feb 13, 2026
Neoadjuvant Pembrolizumab Associated with Chemotherapy in Early Triple-Negative Breast Cancer Patients: Real-World Data from a French Single-Center Experience.

Ichrak Ben Abdallah, Severine Guiu, Xavier Quantin

|Sep 23, 2025
Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2- Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial.

Séverine Guiu, Judith Balmaña, Pablo Lemercier

|Jan 21, 2025
Cathepsins: Novel opportunities for antibody therapeutics in cancer.

Timothée David, Pénélope Desroys du Roure, Aude Mallavialle

|Jul 31, 2024
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer.

Davide Massa, Claudio Vernieri, Lorenzo Nicolè

|Nov 08, 2022
SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity.

Lindsay B Alcaraz, Aude Mallavialle, Caroline Mollevi

Pageof 1

Frequent Collaborators

3 joint publications

William Jacot

2 joint publications

Aude Mallavialle

2 joint publications

Valérie Laurent-Matha

2 joint publications

Thierry Chardès